Letrozole–dasatinib combo shows promise in ER+, HER2– metastatic breast cancer
The combination of the aromatase inhibitor letrozole plus the Src kinase inhibitor dasatinib appears to be well tolerated and effective, with a clinical benefit rate of 71 percent in a cohort of postmenopausal patients with ER-positive, HER2-negative metastatic breast cancer, according to the results of a noncomparative phase II trial.
